Notice NOT-OD-22-214 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-213 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-217 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-215 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-22-059 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models by analyses of relevant pre-clinical and clinical data, and to provide results from optimized models to identify the most promising combination regimens for clinical testing

Funding Opportunity RFA-DA-23-058 from the NIH Guide for Grants and Contracts. As part of the NIH HEAL Initiative, the National Institute on Drug Abuse (NIDA) is releasing a set of interrelated FOAs to create the HEAL Data2Action (HD2A) Program, a coordinated effort to promote the synthesis and real-world application of existing data to improve epidemiology and guide and monitor improvements in service delivery to prevent or treat opioid use disorder (OUD) and pain. Collectively, these projects will improve the quality, timeliness, accessibility and usefulness of data for epidemiology and service delivery in each of the four pillars of the HHS Overdose Prevention Strategy: primary prevention, harm reduction, treatment of opioid use disorder, and recovery support. Separate FOAs have been issued to support multiple HD2A Innovation Projects (RFA-DA-22-051); one HD2A Data Infrastructure Support Center (RFA-DA-22-052); one HD2A Research Adoption Support Center (RFA-DA-22-050); and one HD2A Economics and Modeling Resource Center (RFA-DA-22-049). It is imperative that prospective applicants read all of these related RFAs to better understand the intended purpose and structure of the HD2A Program. This FOA solicits applications for HEAL Data2Action (HD2A) Acceleration Projects. Research Projects will focus on developing data or methods that improves timeliness, quality, accessibility, or usefulness of existing data ecosystems to allow for faster and improved responses and allocation of resources to address the overdose crisis. This FOA invites projects for which preliminary or feasibility data are available, such as from an R21 study or its equivalent. This FOA is a companion to RFA-DA-232-057, which solicits Acceleration and Innovation Project applications for which pilot data are unavailable.

Funding Opportunity RFA-DA-23-057 from the NIH Guide for Grants and Contracts. As part of the NIH HEAL Initiative, the National Institute on Drug Abuse (NIDA) is releasing a set of interrelated RFAs to create the HEAL Data2Action (D2A) Program, a coordinated effort to promote the synthesis and real-world application of existing data to guide and monitor improvements in service delivery to prevent or treat opioid use disorder (OUD) and pain. Collectively, these projects will address gaps in the delivery of evidence-based practices in each of the four pillars of the HHS Overdose Prevention Strategy: primary prevention, harm reduction, treatment of opioid use disorder, and recovery support. Separate FOAs are being issued to support multiple HEAL D2A Innovation Projects (RFA-DA-22-051); one HEAL D2A Data Infrastructure Support Center (RFA-DA-22-052); one HEAL D2A Research Adoption Support Center (RFA-DA-22-050); and one HEAL D2A Economics and Modeling Resource Center (RFA-DA-22-049). It is imperative that prospective applicants read all of these related RFAs to better understand the intended purpose and structure of the HEAL D2A Program.This FOA solicits applications for HEAL D2A Innovation Projects, which are phased awards intended to support local efforts, either within a single system or in cross-sector partnerships, to improve utilization of data to drive prediction and real-time proactive responses to the overdose crisis.

Notice NOT-AG-22-038 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-027 from the NIH Guide for Grants and Contracts

Notice NOT-AI-22-064 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-22-029 from the NIH Guide for Grants and Contracts. Reissue RFA-NS-11-009: The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite applications to participate as a Clinical Coordinating Center in the Network for Excellence in Neuroscience Clinical Trials. This clinical research network will develop and conduct multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network will provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network will not be specific to one disease, it will have the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for the Clinical Coordinating Center (CCC). Separate FOAs solicit applications for the Clinical Sites and the Data Coordinating Center.

Funding Opportunity RFA-NS-22-030 from the NIH Guide for Grants and Contracts. Reissue RFA-NS-11-010: The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite applications to participate as a Data Coordinating Center in the Network for Excellence in Neuroscience Clinical Trials. This clinical research network will develop and conduct multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network will provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network will not be specific to one disease, it will have the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for the Data Coordinating Center (DCC). Separate FOAs solicit applications for the Clinical Sites and the Clinical Coordinating Center.

Funding Opportunity RFA-NS-22-031 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network provides a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network is not specific to one disease, it has the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for Clinical Sites. Separate FOAs solicit applications for the Clinical Coordinating Center and the Data Coordinating Center.

Funding Opportunity RFA-DA-23-039 from the NIH Guide for Grants and Contracts. This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to either support or refute a stated hypothesis about brain function. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed.

Funding Opportunity RFA-MH-22-271 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts

Funding Opportunity RFA-MH-22-270 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts

Funding Opportunity RFA-TR-22-032 from the NIH Guide for Grants and Contracts. This FOA provides support using the SBIR cooperative agreement mechanisms for the development, regulatory qualification and commercialization of alternative approaches methods (NAMs) that specifically utilizes the neuromuscular junction Tissue Chips (TC) platforms that will replace the LD50 assay (mouse lethality bioassay (MLB) as a potency assay for botulinum toxin. The NIH NCATS and FDA are partners in this FOA and will collaborate and coordinate efforts with award recipients. The goal of this collaboration is to establish the Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) as a Drug Development Tool (DDT). A main objective for this funding opportunity would be to position BoT PATCh as an alternative test method that can be utilized as a stand-alone replacement for MLB. As a cooperative agreement, small business concerns (SBCs) will be expected to work with NIH and FDA staff to develop and implement the final validation plan for the proposed alternative test method.

Funding Opportunity RFA-TR-22-031 from the NIH Guide for Grants and Contracts. This FOA provides support using the STTR cooperative agreement mechanisms for the development, regulatory qualification and commercialization of alternative approaches methods (NAMs) that specifically utilizes the neuromuscular junction Tissue Chips (TC) platforms that will replace the LD50 assay (mouse lethality bioassay (MLB) as a potency assay for botulinum toxin. The NIH NCATS and FDA are partners in this FOA and will collaborate and coordinate efforts with award recipients. The goal of this collaboration is to establish the Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) as a Drug Development Tool (DDT). A main objective for this funding opportunity would be to position BoT PATCh as an alternative test method that can be utilized as a stand-alone replacement for MLB. As a cooperative agreement, small business concerns (SBCs) will be expected to work with NIH and FDA staff to develop and implement the final validation plan for the proposed alternative test method.

Notice NOT-RM-23-004 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-047 from the NIH Guide for Grants and Contracts